NCT05962424 HNC: Human Neural Circuits Electrophysiology During Cognition
| NCT ID | NCT05962424 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Stanford University |
| Condition | Psychiatric Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2023-10-05 |
| Primary Completion | 2030-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 120 participants in total. It began in 2023-10-05 with a primary completion date of 2030-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to understand how ketamine brings about dissociative symptoms.
Eligibility Criteria
Inclusion Criteria: * Patient in clinical neuro inpatient units at Stanford Medical Center * Age \>18 years old * Female participants are expected to use an effective method of birth control throughout the study which includes: hormonal methods (birth control pills, patches, injections, vaginal ring or implants), barrier methods (condom or diaphragm) used with spermicide, intrauterine device (IUD), or abstinence (no sex) Exclusion Criteria: * Lifetime psychotic disorder * Pregnant or nursing females * Prior adverse ketamine response * Use of ketamine in past 7 days
Contact & Investigator
Karl Deisseroth, MD, PhD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT05962424 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psychiatric Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05962424 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05962424 currently recruiting?
Yes, NCT05962424 is actively recruiting participants. Contact the research team at arjayc@stanford.edu for enrollment information.
Where is the NCT05962424 trial being conducted?
This trial is being conducted at Palo Alto, United States.
Who is sponsoring the NCT05962424 clinical trial?
NCT05962424 is sponsored by Stanford University. The principal investigator is Karl Deisseroth, MD, PhD at Stanford University. The trial plans to enroll 120 participants.